For the Inventor, By the Inventor

Enter assignee name

Sylentis Sau

USPTO Granted Patents = 25

CIPO Patents = 3

EPO Patents = 8

Trademarks = 5

Forward Citations = 81

Loading Chart...

Loading Chart...

32 inventors (with patents filed for the assignee):

Ana I Jiménez (13 out of 13 patents)

Ángela Sesto (13 out of 13 patents)

Irene Gascón (12 out of 12 patents)

4. José P Román (12 out of 12 patents)

5. Gonzalo González De Buitrago (11 out of 11 patents)

6. Ana Isabel Jimenez (6 out of 6 patents)

7. Tamara Martinez (5 out of 5 patents)

8. Covadonga Pañeda (4 out of 4 patents)

9. Ana Isabel Jimenez Anton (4 out of 4 patents)

10. Victoria Gonzalez Fajardo (3 out of 3 patents)

11. Veronica Ruz Palomar (3 out of 3 patents)

12. Angela Sesto Yague (2 out of 2 patents)

13. María Concepción Jiménez Gomez (2 out of 2 patents)

14. Marta Lopez-Fraga (1 out of 1 patent)

15. Tamara Martinez Valcarel (1 out of 1 patent)

25 patents: Sort by Forward Citations

1. 10752896 - siRNA and their use in methods and compositions for inhibiting the expression of the NRARP gene (2020-08-25),

2. 10167473 - SiRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene (2019-01-01),

3. 10017766 - SiRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene (2018-07-10),

4. 10011837 - SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions (2018-07-03),

5. 10011832 - SiRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions (2018-07-03),

6. 9951338 - siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene (2018-04-24),

7. 9808479 - SiRNA and their use in methods and compositions for the treatment and / or prevention of eye conditions (2017-11-07),

8. 9018183 - siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions (2015-04-28),

9. 8951982 - Methods and compositions for the treatment of eye disorders with increased intraocular pressure (2015-02-10),

10. 8871729 - Treatment of CNS conditions (2014-10-28),

11. 8703731 - Sphingosine-bound siRNA (2014-04-22),

12. 8389490 - Methods and compositions for the treatment of eye disorders with increased intraocular pressure (2013-03-05),

13. 8354385 - Modulation of TRPV expression levels (2013-01-15),

14. 8258110 - Methods and compositions for the treatment of eye disorders with increased intraocular pressure (2012-09-04),

15. 8252759 - Methods and compositions for the treatment of eye disorders with increased intraocular pressure (2012-08-28),

Sylentis SAU is a biotechnology company that specializes in the discovery and development of new drugs to treat ocular diseases. Their innovative approach focuses on RNA interference (RNAi) technology to silence specific genes involved in the progression of eye diseases, aiming to provide safe and effective treatments for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

25 Patents

#16 in Madrid

#73 in Spain

#24,928 in the World

Sylentis Sau

Forward Citations = 81

32 inventors:

Ana I Jiménez (13 out of 13 patents)

Ángela Sesto (13 out of 13 patents)

Irene Gascón (12 out of 12 patents)

4. José P Román (12 out of 12 patents)

5. Gonzalo González De Buitrago (11 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…